RAD52 and neoplasm: Since FANCJ is a tumor suppressor and is associated with a broad range of cancers (54), inhibition of RAD52 in combination with G4-stabilizing drugs provides new strategies for targeted cancer treatment of FANCJ-deficient tumors.